PriceTargets.com logo

Alkermes - ALKS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $35.38
  • Forecasted Upside: 45.82%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$24.26 As of 04/23/2024 01:00 AM ET
▲ +0.19 (0.79%)

This chart shows the closing price for ALKS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alkermes Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALKS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALKS

Analyst Price Target is $35.38
▲ +45.82% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $35.38, with a high forecast of $50.00 and a low forecast of $25.00. The average price target represents a 45.82% upside from the last price of $24.26.

This chart shows the closing price for ALKS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in Alkermes. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$35.00Low
4/9/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$42.00 ➝ $50.00Low
4/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$39.00Low
3/19/2024Robert W. BairdInitiated CoverageOutperform$37.00Low
2/20/2024UBS GroupDowngradeNeutral ➝ Sell$25.00Low
2/16/2024Piper SandlerBoost TargetOverweight ➝ Overweight$35.00 ➝ $39.00Low
1/2/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$27.00 ➝ $29.00Low
11/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral$33.00Low
10/27/2023Piper SandlerLower TargetOverweight ➝ Overweight$37.00 ➝ $35.00Low
10/26/2023MizuhoLower TargetBuy ➝ Buy$37.00 ➝ $35.00Low
10/24/2023Evercore ISIUpgradeIn-Line ➝ OutperformLow
10/17/2023UBS GroupInitiated CoverageNeutral$31.00Low
7/27/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$34.00Low
7/10/2023Cantor FitzgeraldReiterated RatingOverweightLow
6/7/2023Piper SandlerBoost Target$35.00 ➝ $37.00Low
6/7/2023MizuhoBoost Target$36.00 ➝ $40.00Low
4/27/2023HC WainwrightBoost Target$32.00 ➝ $34.00Low
4/25/2023JPMorgan Chase & Co.Boost Target$29.00 ➝ $31.00Low
4/11/2023MizuhoBoost TargetBuy$36.00 ➝ $37.00Low
2/17/2023HC WainwrightReiterated RatingNeutral$32.00Low
2/16/2023Stifel NicolausBoost Target$30.00Low
1/8/2023Bank of AmericaBoost Target$27.00 ➝ $28.00Low
12/6/2022JPMorgan Chase & Co.Lower TargetNeutral$33.00 ➝ $29.00Low
11/22/2022MizuhoBoost TargetBuy$34.00 ➝ $36.00Low
11/3/2022Piper SandlerUpgradeNeutral ➝ Overweight$26.00 ➝ $30.00Low
10/14/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$27.00 ➝ $25.00Low
8/16/2022Piper SandlerInitiated CoverageNeutral$26.00Low
7/28/2022MizuhoLower TargetBuy$36.00 ➝ $34.00Low
7/27/2022Stifel NicolausBoost Target$28.00Low
4/28/2022MizuhoBoost Target$35.00 ➝ $36.00High
4/28/2022HC WainwrightBoost Target$30.00 ➝ $32.00High
4/27/2022Stifel NicolausBoost Target$24.00 ➝ $27.00High
4/21/2022SVB LeerinkBoost TargetMarket Perform$24.00 ➝ $25.00Low
4/20/2022The Goldman Sachs GroupInitiated CoverageBuy$35.00Medium
3/22/2022CitigroupBoost TargetNeutral$22.00 ➝ $26.00High
2/17/2022MizuhoBoost Target$33.00 ➝ $35.00High
1/27/2022Cantor FitzgeraldUpgradeHold ➝ Overweight$32.00High
12/1/2021CitigroupInitiated CoverageNeutral$22.00High
11/9/2021MizuhoLower TargetNeutral$36.00 ➝ $33.00High
11/9/2021SVB LeerinkLower TargetMarket Perform$27.00 ➝ $24.00High
10/28/2021HC WainwrightBoost TargetNeutral$25.00 ➝ $30.00Medium
10/27/2021Stifel NicolausBoost TargetHold$25.00 ➝ $29.00Medium
10/6/2021Jefferies Financial GroupUpgradeHold ➝ Buy$36.00High
9/10/2021MizuhoReiterated RatingBuy$33.00 ➝ $36.00Medium
9/2/2021Bank of AmericaDowngradeNeutral ➝ Underperform$25.00 ➝ $27.00Low
7/29/2021SVB LeerinkBoost TargetMarket Perform$23.00 ➝ $25.00Low
7/29/2021MizuhoBoost TargetBuy$29.00 ➝ $33.00Low
6/2/2021HC WainwrightBoost TargetNeutral$24.00 ➝ $25.00Low
6/1/2021MizuhoReiterated RatingBuy$29.00High
4/29/2021HC WainwrightBoost TargetNeutral$23.00 ➝ $24.00Low
4/26/2021MizuhoBoost TargetBuy$28.00 ➝ $29.00High
1/7/2021MizuhoBoost Target$24.00 ➝ $28.00N/A
12/11/2020SVB LeerinkBoost TargetMarket Perform$18.00 ➝ $23.00Medium
11/10/2020HC WainwrightReiterated RatingHoldLow
10/15/2020MizuhoUpgradeNeutral ➝ Buy$19.00 ➝ $24.00Low
10/7/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/30/2020Bank of AmericaLower TargetNeutral$21.00 ➝ $19.00Medium
9/21/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
7/30/2020HC WainwrightReiterated RatingHold$23.00Medium
7/30/2020MizuhoBoost TargetNeutral$16.00 ➝ $19.00High
7/30/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$19.00 ➝ $15.00High
4/30/2020HC WainwrightReiterated RatingNeutral$25.00 ➝ $23.00High
4/29/2020Piper SandlerLower TargetNeutral$22.00 ➝ $21.00High
4/29/2020Stifel NicolausLower TargetAverage ➝ Hold$20.00 ➝ $17.00High
4/29/2020MizuhoReiterated RatingHold$16.00High
4/2/2020Morgan StanleyLower TargetEqual Weight$20.00 ➝ $16.00Low
3/23/2020Bank of AmericaLower TargetNeutral$20.00 ➝ $17.00Medium
2/14/2020HC WainwrightLower TargetNeutral$26.00 ➝ $25.00High
2/14/2020Bank of AmericaDowngradeBuy ➝ Neutral$31.00 ➝ $20.00High
2/14/2020CowenReiterated RatingBuy$28.00High
2/13/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $21.00Low
2/13/2020Stifel NicolausLower TargetHold$23.00 ➝ $20.00Low
2/5/2020MizuhoInitiated CoverageNeutral$19.00Medium
1/31/2020Wolfe ResearchUpgradeUnderperform ➝ Peer Perform$21.00Low
1/24/2020SVB LeerinkReiterated RatingMarket PerformLow
1/24/2020CowenReiterated RatingBuyHigh
11/1/2019HC WainwrightLower TargetNeutral$28.00 ➝ $26.00Low
10/23/2019Stifel NicolausLower TargetHold$25.00 ➝ $23.00High
10/18/2019HC WainwrightReiterated RatingHold$28.00Low
9/13/2019CowenSet TargetBuy$34.00High
9/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal$30.00 ➝ $20.00Medium
7/26/2019CitigroupSet TargetHold$25.00N/A
7/25/2019Piper Sandler CompaniesLower TargetNeutral$30.00 ➝ $22.00Medium
7/15/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$27.00High
5/31/2019HC WainwrightInitiated CoverageNeutral ➝ Neutral$28.00 ➝ $28.00High
5/1/2019CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $33.00High
4/26/2019Credit Suisse GroupSet TargetSell$28.00Medium
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 5 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 7 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 15 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 28 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 18 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 14 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 14 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $24.26
Low: $24.06
High: $24.63

50 Day Range

MA: $27.74
Low: $23.76
High: $32.56

52 Week Range

Now: $24.26
Low: $22.01
High: $33.71

Volume

1,245,764 shs

Average Volume

1,907,468 shs

Market Capitalization

$4.10 billion

P/E Ratio

11.72

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Alkermes?

The following sell-side analysts have issued stock ratings on Alkermes in the last year: Bank of America Co., Cantor Fitzgerald, Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Piper Sandler, Robert W. Baird, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for ALKS.

What is the current price target for Alkermes?

8 Wall Street analysts have set twelve-month price targets for Alkermes in the last year. Their average twelve-month price target is $35.38, suggesting a possible upside of 45.8%. Jefferies Financial Group Inc. has the highest price target set, predicting ALKS will reach $50.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $25.00 for Alkermes in the next year.
View the latest price targets for ALKS.

What is the current consensus analyst rating for Alkermes?

Alkermes currently has 1 sell rating, 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALKS.

What other companies compete with Alkermes?

Other companies that are similar to Alkermes include Madrigal Pharmaceuticals, Eidos Therapeutics, Amicus Therapeutics, Ionis Pharmaceuticals and Geron. Learn More about companies similar to Alkermes.

How do I contact Alkermes' investor relations team?

Alkermes' physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company's listed phone number is (531) 772-8000 and its investor relations email address is [email protected]. The official website for Alkermes is www.alkermes.com. Learn More about contacing Alkermes investor relations.